2022-12-202022-12-202021-07-27Ohmura, S., Marchetto, A., Orth, M.F., Li, J., Jabar, S., Ranft, A.,...,Grünewald, T.G.P. (2021). Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Molecular Cancer, 20 (1), 97. https://doi.org/10.1186/s12943-021-01393-9.1476-4598https://hdl.handle.net/11441/140688Ewing sarcoma (EwS) is an aggressive bone- or soft tissue-associated malignancy, characterised by the fusion oncoprotein EWSR1-FLI1 [1]. Over the past decades further therapeutic development for this devastating childhood tumour has remained relatively stagnant [2], especially for patients with metastatic or recurrent disease [3, 4]. To develop more effective and specific treatment options we investigated potential therapeutic targets by exploring putative downstream genes of EWSR1-FLI1. (extracted from the main text)application/pdf7 p.engAtribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/Ewing sarcomaRRM2Targeted therapyPrognostic biomarkerPaediatric oncologyTriapineChemoresistanceinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccess10.1186/s12943-021-01393-9